News | January 08, 2014

Zio Service Identifies More Cardiac Arrhythmias Than Traditional Holter Monitors

Study published online in American Journal of Medicine

clinical trial study irhythm holter monitors zio report patch ecg ep lab
January 8, 2014 — iRhythm Technologies announced that a prospective study by Scripps Translational Science Institute (STSI) has found that use of the company's Zio Service significantly increased detection of cardiac arrhythmias, compared to use of the traditional Holter monitor. The findings were published and made publicly accessible online in the January issue of the American Journal of Medicine.
 
"This is the first large prospective validation that this new technology superseded the device invented by Norman Holter in 1949," said study senior author Eric Topol, M.D., cardiologist, director, STSI, and chief academic officer, Scripps Health. "By tracking every heart beat for up to two weeks, the Zio Service proved to be significantly more sensitive than the standard Holter, which uses multiple wires and typically is only used or tolerated for 24 hours.”
 
"For millions of people who present each year with suspected arrhythmia, this may prove to be the new standard for capturing the culprit heart rhythm electrical disturbance, most commonly atrial fibrillation which carries a significant risk of stroke," Topol continued.
 
The prospective study included 146 consecutive Scripps Health patients who were referred for evaluation of cardiac arrhythmias and underwent simultaneous ambulatory electrocardiogram (ECG) monitoring with a Zio Patch, which is worn on the chest and continuously records heartbeats for up to 14 days, and a conventional 24-hour Holter monitor, a portable machine with multiple wires that connect to electrodes on the chest. Over the total wear time of both devices, the Zio Service detected 57 percent more arrhythmia events compared to the Holter monitor (96 versus 61), primarily due to prolonged monitoring. Physicians also reported that they arrived at a definitive diagnosis in 90 percent of cases using the Zio Service, compared to 64 percent with the Holter monitor. Further, 81 percent of patients reported they preferred the Zio Patch versus the Holter monitor.
 
"Traditional cardiac monitoring options are limited in their ability to capture arrhythmias, which are infrequent and often have no symptoms, and because they are hard for patients to comply with," said Kevin King, president and CEO, iRhythm.
 
For more information: www.irhythmtech.com, www.amjmed.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init